Legemiddelforbruket I Norge 2014–2018 Drug Consumption in Norway 2014–2018

Total Page:16

File Type:pdf, Size:1020Kb

Legemiddelforbruket I Norge 2014–2018 Drug Consumption in Norway 2014–2018 LEGEMIDDELSTATISTIKK 2019:1 Legemiddelforbruket i Norge 2014–2018 Drug Consumption in Norway 2014–2018 Legemiddelforbruket i Norge 2014–2018 Drug Consumption in Norway 2014–2018 Solveig Sakshaug Kristine Olsen Christian Berg Hege Salvesen Blix Live Storehagen Dansie Irene Litleskare Tove Granum Utgitt av Folkehelseinstituttet/Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Mai 2019 Tittel/Title: Legemiddelstatistikk 2019:1 Legemiddelforbruket i Norge 2014–2018/Drug Consumption in Norway 2014–2018 Forfattere/Authors: Solveig Sakshaug (redaktør) Kristine Olsen Christian Berg Hege Salvesen Blix Live Storehagen Dansie Irene Litleskare Tove Granum Bestilling: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no The report is only available as pdf from www.fhi.no Grafisk design omslag: Fete Typer Kontaktinformasjon/Contact information: Folkehelseinstituttet/Norwegian Institute of Public Health P.O.Box 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN:1890-9647 ISBN elektronisk utgave: 978-82-8406-011-8 Sitering/Citation: Sakshaug, S (red), Legemiddelforbruket i Norge 2014–2018 [Drug Consumption in Norway 2014–2018], Legemiddelstatistikk 2019:1, Oslo: Folkehelseinstituttet, 2019. Tidligere utgaver/Previous editions: 1977: Legemiddelforbruket i Norge 1974–1976 1978: Legemiddelforbruket i Norge 1975–1977 1980: Legemiddelforbruket i Norge 1975–1979 1981: Legemiddelforbruket i Norge 1980 1982: Legemiddelforbruket i Norge 1977–1981 1984: Legemiddelforbruket i Norge 1979–1983 1985: Legemiddelforbruket i Norge 1984 1986: Legemiddelforbruket i Norge 1981–1985 1987: Legemiddelforbruket i Norge 1986 1988: Legemiddelforbruket i Norge 1987 1989: Legemiddelforbruket i Norge 1984–1988 1990: Legemiddelforbruket i Norge 1989 1991: Legemiddelforbruket i Norge 1986–1990 1992: Legemiddelforbruket i Norge 1991 1993: Legemiddelforbruket i Norge 1988–1992 1994: Legemiddelforbruket i Norge 1989–1993 1995: Legemiddelforbruket i Norge 1990–1994 1996: Legemiddelforbruket i Norge 1991–1995 1997: Legemiddelforbruket i Norge 1992–1996 1998: Legemiddelforbruket i Norge 1993–1997 1999: Legemiddelforbruket i Norge 1994–1998 2000: Legemiddelforbruket i Norge 1995–1999 2001: Legemiddelforbruket i Norge 1996–2000 2002: Legemiddelforbruket i Norge 1997–2001 2003: Legemiddelforbruket i Norge 1998–2002 2004: Legemiddelforbruket i Norge 1999–2003 2005: Legemiddelforbruket i Norge 2000–2004 2006: Legemiddelforbruket i Norge 2001–2005 2007: Legemiddelforbruket i Norge 2002–2006 2008: Legemiddelforbruket i Norge 2003–2007 2009: Legemiddelforbruket i Norge 2004–2008 2010: Legemiddelforbruket i Norge 2005–2009 2011: Legemiddelforbruket i Norge 2006–2010 2012: Legemiddelforbruket i Norge 2007–2011 2013: Legemiddelforbruket i Norge 2008–2012 2014: Legemiddelforbruket i Norge 2009–2013 2015: Legemiddelforbruket i Norge 2010–2014 2016: Legemiddelforbruket i Norge 2011–2015 2017: Legemiddelforbruket i Norge 2012–2016 2018: Legemiddelforbruket i Norge 2013–2017 Innhold Oppsummering ...................................................................................................................................... 7 Innledning .............................................................................................................................................. 7 Datagrunnlag ......................................................................................................................................... 8 Anatomisk Terapeutisk Kjemisk (ATC) klassifikasjon............................................................................. 9 Måleenheter ........................................................................................................................................ 11 Reseptregisteret .................................................................................................................................. 13 Kommentarer til statistikken ............................................................................................................... 14 Kostnader ............................................................................................................................. 14 Salg i definerte døgndoser (DDD) ........................................................................................ 15 Salg fordelt på reseptkategorier .......................................................................................... 15 Salg per legemiddelgruppe .................................................................................................. 15 Salg av reseptfrie legemidler ............................................................................................... 17 Veterinære legemidler ......................................................................................................... 19 Folkemengde etter alder 2014 – 2018 ................................................................................................ 24 Forkortelser ......................................................................................................................................... 25 Statistikk pr ATC hovedgruppe A Fordøyelsesorganer og stoffskifte .................................................................................................. 26 B Blod og bloddannende organer...................................................................................................... 32 C Hjerte og kretsløp ........................................................................................................................... 35 D Dermatologiske midler ................................................................................................................... 41 G Urogenitalsystem og kjønnshormoner........................................................................................... 43 H Hormoner til systemisk bruk, ekskl. kjønnshormoner og insuliner................................................ 49 J Antiinfektiva til systemisk bruk ...................................................................................................... 52 L Antineoplastiske og immunmodulerende midler .......................................................................... 58 M Muskler og skjelett ......................................................................................................................... 65 N Nervesystemet ............................................................................................................................... 68 P Antiparasitære midler, insekticider og insektmidler ...................................................................... 87 R Respirasjonsorganer ....................................................................................................................... 79 S Sanseorganer .................................................................................................................................. 84 V Varia ............................................................................................................................................... 85 Endring av ATC koder og DDD 2019 .................................................................................................... 87 Legemiddelstatistikk 2019:1•Folkehelseinstituttet 5 Contents Summary ............................................................................................................................................... 7 Introduction ........................................................................................................................................... 7 Data source ............................................................................................................................................ 8 The Anatomical Therapeutic Chemical (ATC) classification system ...................................................... 9 Units of measurement ......................................................................................................................... 11 Norwegian Prescription Database (NorPD) ......................................................................................... 13 Comments to the statistics .................................................................................................................. 14 Cost ......................................................................................................................................... 14 Sales in defined daily dose (DDDs) ......................................................................................... 15 Sales according to prescription category ............................................................................... 15 Turnover per ATC group ......................................................................................................... 15 Sale of non-prescription medicines (OTC) .............................................................................. 15 Veterinary medicines .............................................................................................................. 19 Population by age 2014 - 2018 ............................................................................................................ 24 Abbreviations ...................................................................................................................................... 25 Statistics for each ATC main group A Alimentary tract and metabolism .................................................................................................
Recommended publications
  • Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease
    UnitedHealthcare® Commercial Medical Benefit Drug Policy Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease Policy Number: 2021D0048K Effective Date: April 1, 2021 Instructions for Use Table of Contents Page Related Commercial Policy Coverage Rationale ....................................................................... 1 • Provider Administered Drugs – Site of Care Applicable Codes .......................................................................... 3 Background.................................................................................... 3 Community Plan Policy Benefit Considerations .................................................................. 3 • Intravenous Enzyme Replacement Therapy (ERT) Clinical Evidence ........................................................................... 4 for Gaucher Disease U.S. Food and Drug Administration ............................................. 6 Centers for Medicare and Medicaid Services ............................. 6 References ..................................................................................... 7 Policy History/Revision Information ............................................. 8 Instructions for Use ....................................................................... 8 Coverage Rationale See Benefit Considerations This policy refers to the following drug products, all of which are intravenous enzyme replacement therapies used in the treatment of Gaucher disease: Cerezyme® (imiglucerase) Elelyso® (taliglucerase) VPRIV® (velaglucerase)
    [Show full text]
  • Kengrexal, INN-Cangrelor Tetrasodium
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Kengrexal 50 mg powder for concentrate for solution for injection/infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains cangrelor tetrasodium corresponding to 50 mg cangrelor. After reconstitution 1 mL of concentrate contains 10 mg cangrelor. After dilution 1 mL of solution contains 200 micrograms cangrelor. Excipient with known effect Each vial contains 52.2 mg sorbitol. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for concentrate for solution for injection/infusion. White to off-white lyophilised powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable. 4.2 Posology and method of administration Kengrexal should be administered by a physician experienced in either acute coronary care or in coronary intervention procedures and is intended for specialised use in an acute and hospital setting. Posology The recommended dose of Kengrexal for patients undergoing PCI is a 30 micrograms/kg intravenous bolus followed immediately by 4 micrograms/kg/min intravenous infusion. The bolus and infusion should be initiated prior to the procedure and continued for at least two hours or for the duration of the procedure, whichever is longer. At the discretion of the physician, the infusion may be continued for a total duration of four hours, see section 5.1.
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Sofosbuvir-Based and Elbasvir/Grazoprevir Treatment Fai
    Sofosbuvir-Based and Elbasvir/Grazoprevir Treatment Fai... From www.HCVGuidance.org on September 27, 2021 Sofosbuvir-Based and Elbasvir/Grazoprevir Treatment Failures In general, persons who have experienced treatment failure with a sofosbuvir-based regimen should be retreated with 12 weeks of sofosbuvir/velpatasvir/voxilaprevir. The main exception is persons with genotype 3 and cirrhosis, in whom addition of ribavirin to sofosbuvir/velpatasvir/voxilaprevir for 12 weeks is recommended. Sixteen weeks of glecaprevir/pibrentasvir is an alternative regimen. Elbasvir/grazoprevir treatment failure patients should also be retreated with 12 weeks of sofosbuvir/velpatasvir/voxilaprevir. However, glecaprevir/pibrentasvir for 16 weeks is not recommended as an alternative for this group of patients. Recommended and alternative regimens listed by evidence level and alphabetically for: Sofosbuvir-Based Treatment Failures, With or Without Compensated Cirrhosisa RECOMMENDED DURATION RATING Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 12 weeks I, A mg)/voxilaprevir (100 mg)b ALTERNATIVE DURATION RATING Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) 16 weeks I, A except for NS3/4 protease inhibitor inclusive combination DAA regimen failuresc Not recommended for genotype 3 infection with sofosbuvir/NS5A inhibitor experience. a For decompensated cirrhosis, please refer to the appropriate section. b Genotype 3: Add weight-based ribavirin if cirrhosis is present and there are no contraindications. c This regimen is not recommended for patients with prior exposure to an NS5A inhibitor plus NS3/4 PI regimens (eg. Elbasvir/grazoprevir). Recommended Regimen Sofosbuvir/Velpatasvir/Voxilaprevir The placebo-controlled, phase 3 POLARIS-1 trial evaluated a 12-week course of the daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100mg) in 263 persons with a prior NS5A inhibitor-containing DAA regimen failure.
    [Show full text]
  • Hepatitis C Treatment
    Hepatitis C Treatment The goal of treatment for hepatitis C virus (HCV) is to cure the virus, which can be done with a combination of drugs. The specific meds used and the duration of treatment depend on a number of factors, including HCV genotype (genetic structure of the virus), viral load, past treatment experience, degree of liver damage, ability to tolerate the prescribed treatment, and whether the person is waiting for a liver transplant or is a transplant recipient. In some cases, HCV treatment may be limited by your health insurance plan or drug formulary. Here’s information about each type, or class, of approved HCV treatment along with drugs in the late stages of development: Multi-Class Combination Drugs Brand Name Generic Name Status Pharmaceutical Company Epclusa* sofosbuvir + velpatasvir Approved Gilead Sciences Harvoni* ledipasvir + sofosbuvir Approved Gilead Sciences Mavyret glecaprevir + pibrentasvir Approved AbbVie Vosevi sofosbuvir/velpatasvir/ Approved Gilead Sciences voxilaprevir Zepatier elbasvir + grazoprevir Approved Merck n/a daclatasvir + asunaprevir + Phase III Bristol-Myers Squibb beclabuvir *generic available What are they? Multi-class combination drugs are a combination of drugs formulated into a single pill or package of pills. For instance, the drug Harvoni combines two drugs, ledipasvir and sofosbuvir. Ledipasvir is an NS5A inhibitor and is only sold as part of Harvoni; sofosbuvir may be prescribed separately under the brand name of Sovaldi. Pegylated Interferon Alfa Brand Name Generic Name Status Pharmaceutical Company Pegasys peginterferon alfa-2a Approved Genentech What are they? Interferon is a protein made by the immune system, named because it interferes with viral reproduction. In addition, interferon signals the immune system to recognize and respond to microorganisms, including viral and bacterial infections.
    [Show full text]
  • BCBSVT Specialty Drug List Effective 2021.07.01.Xlsx
    Effective Date: 07/01/2021 SPECIALTY DRUG LIST Revised Date: 05/07/2021 DOSAGE EXCLUDED ON NATIONAL DRUG CLASS DRUG NAME GENERIC NAME FORM PERFORMANCE FORMULARY ANEMIA ARANESP SOLN DARBEPOETIN ALFA SOLN INJ ANEMIA ARANESP SOSY DARBEPOETIN ALFA SOLN PREFILLED SYRINGE ANEMIA EPOGEN SOLN EPOETIN ALFA INJ X ANEMIA PROCRIT SOLN EPOETIN ALFA INJ X ANEMIA REBLOZYL SOLR LUSPATERCEPT-AAMT FOR SUBCUTANEOUS INJ ANEMIA RETACRIT SOLN EPOETIN ALFA-EPBX INJ ANTI-GOUT AGENT KRYSTEXXA SOLN PEGLOTICASE INJ (FOR IV INFUSION) ANTI-INFECTIVE PREVYMIS SOLN LETERMOVIR IV SOLN ANTI-INFECTIVE PREVYMIS TABS LETERMOVIR TAB ASTHMA CINQAIR SOLN RESLIZUMAB IV INFUSION SOLN ASTHMA FASENRA SOSY BENRALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE ASTHMA FASENRA PEN SOAJ BENRALIZUMAB SUBCUTANEOUS SOLN AUTO-INJECTOR ASTHMA NUCALA SOAJ MEPOLIZUMAB SUBCUTANEOUS SOLUTION AUTO-INJECTOR ASTHMA NUCALA SOLR MEPOLIZUMAB FOR INJ ASTHMA NUCALA SOSY MEPOLIZUMAB SUBCUTANEOUS SOLUTION PREF SYRINGE ASTHMA XOLAIR SOLR OMALIZUMAB FOR INJ ASTHMA XOLAIR SOSY OMALIZUMAB SUBCUTANEOUS SOLN PREFILLED SYRINGE CARDIOVASCULAR VYNDAMAX CAPS TAFAMIDIS CAP CARDIOVASCULAR VYNDAQEL CAPS TAFAMIDIS MEGLUMINE (CARDIAC) CAP CENTRAL NERVOUS SYSTEM AGENTS AUSTEDO TABS DEUTETRABENAZINE TAB CENTRAL NERVOUS SYSTEM AGENTS ENSPRYNG SOSY SATRALIZUMAB-MWGE SUBCUTANEOUS SOLN PREF SYRINGE CENTRAL NERVOUS SYSTEM AGENTS HETLIOZ CAPS TASIMELTEON CAPSULE CENTRAL NERVOUS SYSTEM AGENTS HETLIOZ LQ SUSP TASIMELTEON ORAL SUSP CHEMOTHERAPY PROTECTANT AMIFOSTINE SOLR AMIFOSTINE CRYSTALLINE FOR INJ CHEMOTHERAPY PROTECTANT ELITEK
    [Show full text]
  • Treatment of HCV in Persons with Renal Impairment
    © Hepatitis C Online PDF created September 29, 2021, 2:18 pm Treatment of HCV in Persons with Renal Impairment This is a PDF version of the following document: Module 6: Treatment of Key Populations and Unique Situations Lesson 3: Treatment of HCV in Persons with Renal Impairment You can always find the most up to date version of this document at https://www.hepatitisC.uw.edu/go/key-populations-situations/treament-renal-impairment/core-concept/all. Background Epidemiology of Hepatitis C Infection and Renal Disease Persons infected with hepatitis C virus (HCV) can develop kidney disease as a result of extrahepatic manifestation of HCV or as a disease process independent of the HCV infection. In addition, hemodialysis has been a risk factor for acquiring HCV infection, as shown by numerous outbreaks and HCV cross-infections that have occurred in hemodialysis units.[1,2,3,4] Earlier studies conducted in western countries have shown an HCV prevalence in hemodialysis patients that ranged from 2.6 to 23%, with higher prevalence correlating with longer duration of hemodialysis.[5,6,7] The risk of HCV transmission in hemodialysis units has declined due to improved testing and infection control practices.[8,9] Interaction of Hepatitis C Infection and Renal Disease Several studies have shown that patients on chronic hemodialysis have an increased overall mortality risk if they have chronic hepatitis C infection (when compared with those on dialysis who do not have hepatitis C infection).[10,11] There are also some data showing that chronic hepatitis C may be a risk factor for developing renal cell carcinoma.[12] Chronic hepatitis C infection has also been associated with an accelerated course of renal disease, including in persons with HIV coinfection.[13,14] Extrahepatic manifestations related to HCV, including immune complex-related renal disease, can require urgent HCV treatment to resolve or prevent further organ damage.
    [Show full text]
  • Epclusa, INN-Sofosbuvir/Velpatasvir
    26 May 2016 EMA/399285/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Epclusa International non-proprietary name: sofosbuvir / velpatasvir Procedure No. EMEA/H/C/004210/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ...................................................................................... 7 1.2. Steps taken for the assessment of the product ......................................................... 8 2. Scientific discussion ................................................................................ 9 2.1. Introduction......................................................................................................... 9 2.2. Quality aspects .................................................................................................. 10 2.2.1. Introduction .................................................................................................... 10 2.2.2. Active substance ...........................................................................................
    [Show full text]
  • Transaction Drug 1St (DIN) 2Nd (PIN) 3Rd (PIN) 4Th (PIN) 5Th (PIN) 6Th
    Transaction Drug 1st (DIN) 2nd (PIN) 3rd (PIN) 4th (PIN) 5th (PIN) 6th (PIN) 7th (PIN) 8th (PIN) 9th (PIN) 10th (PIN) 11th (PIN) 12th (PIN) 13th (PIN) Alectinib (Alecensaro®) 02458136 00904400 − − − − − − − − − − − 150 mg capsule Alemtuzumab (LemtradaTM) 02418320 00904161 00904162 00904163 00904164 00904165 00904166 00904167 − − − − − 12 mg / 1.2 mL single-use vial Asfotase alfa (Strensiq®) 02444615 00904483 00904484 00904485 − − − − − − − − − 18 mg / 0.45 mL single-use vial Asfotase alfa (Strensiq®) 02444623 00904486 00904487 00904488 00904489 00904490 − − − − − − − 28 mg / 0.7 mL single-use vial Asfotase alfa (Strensiq®) 02444631 00904491 00904492 00904493 − − − − − − − − − 40 mg / 1 mL single-use vial Asfotase alfa (Strensiq®) 02444658 00904494 00904495 00904496 00904497 00904498 00904499 00904500 00904501 00904502 00904504 00904505 − 80 mg / 0.8 mL single-use vial Canakinumab (Ilaris®) 150 mg/mL powder for solution 02344939 00904404 00903809 00904410 − − − − − − − − − for injection Canakinumab (Ilaris®) 02460351 00904405 00904411 00904412 − − − − − − − − − 150 mg/mL solution for injection Ceftolozane / Tazobactam 02446901 00904433 − − − − − − − − − − − (Zerbaxa®) 1 g / 0.5 g vial Cerliponase Alfa (Brineura®) 150 mg / 5 mL solution for 02484013 00904634 00904635 00904636 − − − − − − − − − intracerebroventricular infusion Cladribine (MavencladTM) 02470179 00904524 00904525 00904526 00904642 − − − − − − − − 10 mg tablet Cysteamine (ProcysbiTM) 02464713 00904354 00904355 − − − − − − − − − − 75 mg delayed-release capsule Daclastavir (DaklinzaTM)
    [Show full text]
  • Heparin Induced Thrombocytopenia – Adult – Inpatient– Clinical Practice Guideline
    Heparin Induced Thrombocytopenia – Adult – Inpatient– Clinical Practice Guideline Table of Contents EXECUTIVE SUMMARY ........................................................................................................... 2 SCOPE ...................................................................................................................................... 6 METHODOLOGY ...................................................................................................................... 6 DEFINITIONS (OPTIONAL): ..................................................................................................... 7 INTRODUCTION ....................................................................................................................... 7 RECOMMENDATIONS .............................................................................................................. 7 BENEFITS/HARMS OF IMPLEMENTATION ...........................................................................17 IMPLEMENTATION PLAN AND TOOLS ........................ERROR! BOOKMARK NOT DEFINED. REFERENCES .........................................................................................................................17 APPENDIX A ............................................................................................................................17 Note: Active Table of Contents Click to follow link CPG Contact for Changes: CPG Contact for Content: Name: Philip J Trapskin, PharmD,BCPS Name: Anne E. Rose, PharmD Phone Number: 263-1328 Phone Number:
    [Show full text]
  • Evaluation and Management of Chronic Hepatitis C Virus Infection
    EVALUATION AND MANAGEMENT OF CHRONIC HEPATITIS C VIRUS (HCV) INFECTION Federal Bureau of Prisons Clinical Guidance MAY 2017 Federal Bureau of Prisons (BOP) Clinical Guidance is made available to the public for informational purposes only. The BOP does not warrant this guidance for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient- specific. Consult the BOP Health Management Resources Web page to determine the date of the most recent update to this document: http://www.bop.gov/resources/health_care_mngmt.jsp. Federal Bureau of Prisons Evaluation and Management of Chronic HCV Infection Clinical Guidance May 2017 WHAT’S NEW IN BOP GUIDANCE REGARDING HCV INFECTION? The major changes included in this May 2017 update to the BOP guidance on chronic HCV infection are based primarily on the April 2017 changes to the American Association for the Study of Liver Diseases (AASLD) guidelines, as follows: • The term resistance-associated substitutions (RASs) is now being used instead of resistance- associated variants (RAVs). • Anti-HBs and anti-HBc, in addition to HBsAg, are recommended for baseline testing of hepatitis B status (see LABORATORY TESTS under BASELINE EVALUATION). • Ledipasvir/sofosbuvir once daily for eight weeks is now an AASLD-recommended regimen for treatment in a subgroup of HCV-infected persons who have genotype 1a or 1b, have an HCV viral load <6 million IU/ml, and are treatment-naïve—but who are not black, are not HIV-coinfected, and do not have cirrhosis.
    [Show full text]
  • Vpriv-Pm-En.Pdf
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrVPRIV® velaglucerase alfa Powder for Solution for Injection 400 U/vial, Intravenous Enzyme Replacement Therapy ATC code: A16AB10 Takeda Canada Inc. Date of Initial Approval: 22 Adelaide Street West, Suite 3800 October 1, 2010 Toronto Ontario M5H 4E3 Date of Revision: December 21, 2020 Submission Control No: 241844 VPRIV® and the VPRIV Logo® are registered trademarks of Shire Human Genetic Therapies, Inc. TAKEDA™ and the TAKEDA Logo® are trademarks of Takeda Pharmaceutical Company Limited, used under license. Page 1 of 24 RECENT MAJOR LABEL CHANGES Warnings and Precautions, Immunogenicity (8) 9/2020 Warnings and Precautions, Infusion-Related Reactions (8) 9/2020 Warnings and Precautions, Breast-feeding (8.1.2) 9/2020 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ................................................................. 4 1 INDICATIONS .................................................................................................................4 2 CONTRAINDICATIONS ..................................................................................................4 4 DOSAGE AND ADMINISTRATION ................................................................................ 4 4.1 Dosing Considerations ..........................................................................................4 4.2 Recommended Dose and Dosage Adjustment ....................................................... 4 4.3 Administration .......................................................................................................4
    [Show full text]